Apyx Medical Corp
NASDAQ:APYX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Apyx Medical Corp
NASDAQ:APYX
|
US |
|
C
|
Chai Watana Tannery Group PCL
SET:CWT
|
TH |
|
JCDecaux SE
PAR:DEC
|
FR |
|
Ooedo Onsen Reit Investment Corp
TSE:3472
|
JP |
|
R
|
Riyal Investment and Development Company SCJSC
SAU:9584
|
SA |
|
Trane Technologies PLC
NYSE:TT
|
IE |
|
S
|
Suzhou Fushilai Pharmaceutical Co Ltd
SZSE:301258
|
CN |
|
C
|
Central Vietnam Metal Corp
VN:KMT
|
VN |
|
Hercules Hoists Ltd
NSE:HERCULES
|
IN |
|
FirstService Corp
TSX:FSV
|
CA |
|
Meridia Real Estate III Socimi SA
MAD:YMRE
|
ES |
|
Cohu Inc
NASDAQ:COHU
|
US |
|
Sanofi SA
MIL:1SAN
|
FR |
Apyx Medical Corp
Apyx Medical Corp. operates as an energy-based medical technology company. The company is headquartered in Clearwater, Florida and currently employs 272 full-time employees. The firm operates through two segments: Advanced Energy and original equipment manufacturer (OEM). Its Advanced Energy product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. These product lines consist of a multifunction generator, a handpiece, and a supply of helium gas. Its primary focus is on the cosmetic surgery market, where Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. The firm designs, develops, and manufactures electrosurgical equipment by producing generators and related accessories for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for its energy-based designs.
Apyx Medical Corp. operates as an energy-based medical technology company. The company is headquartered in Clearwater, Florida and currently employs 272 full-time employees. The firm operates through two segments: Advanced Energy and original equipment manufacturer (OEM). Its Advanced Energy product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. These product lines consist of a multifunction generator, a handpiece, and a supply of helium gas. Its primary focus is on the cosmetic surgery market, where Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. The firm designs, develops, and manufactures electrosurgical equipment by producing generators and related accessories for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for its energy-based designs.
Revenue beat: Q4 revenue was a record $19.2 million, up from $14.2 million a year ago, driven largely by AYON system sales.
AYON launch: Full commercial launch in September 2025 is driving strong demand; management says launch metrics have exceeded expectations.
Product update: Follow‑up 510(k) for power‑assisted liposuction submitted in Q4; company expects clearance in mid‑2026 and says the function can be activated on systems already in the field.
Market tailwind: Company views widespread GLP‑1 adoption as a durable tailwind for body contouring and skin‑laxity treatments, citing Renuvion as a best‑in‑class solution.
Profitability progress: Gross profit rose to $12.0 million; company reported income from operations of $11,000 and adjusted EBITDA of $0.7 million in Q4.
2026 guidance: Revenue guidance of $57.5 million to $58.5 million (Surgical Aesthetics $53M–$54M; OEM ~$4.5M); gross margin guidance 61%–62%; operating expenses not to exceed $45 million.
Cash runway: Cash and cash equivalents were $31.7 million at year‑end; company expects cash through 2027 and to be cash‑flow positive by Q4 2026.
Commercial investment: Management is hiring experienced sales talent to support AYON adoption while keeping prior cost reductions in place.
